Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Synthesis of small peptide compounds, molecular docking, and inhibitory activity evaluation against phosphatases PTP1B and SHP2.

Kostrzewa T, Sahu KK, Gorska-Ponikowska M, Tuszynski JA, Kuban-Jankowska A.

Drug Des Devel Ther. 2018 Dec 5;12:4139-4147. doi: 10.2147/DDDT.S186614. eCollection 2018.

2.

Inhibitory Activity of Iron Chelators ATA and DFO on MCF-7 Breast Cancer Cells and Phosphatases PTP1B and SHP2.

Kuban-Jankowska A, Sahu KK, Gorska-Ponikowska M, Tuszynski JA, Wozniak M.

Anticancer Res. 2017 Sep;37(9):4799-4806.

PMID:
28870898
3.

Lipoic Acid Decreases the Viability of Breast Cancer Cells and Activity of PTP1B and SHP2.

Kuban-Jankowska A, Gorska-Ponikowska M, Wozniak M.

Anticancer Res. 2017 Jun;37(6):2893-2898.

PMID:
28551626
4.

Benzo[c][1,2,5]thiadiazole derivatives: A new class of potent Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.

Wang WL, Chen XY, Gao Y, Gao LX, Sheng L, Zhu J, Xu L, Ding ZZ, Zhang C, Li JY, Li J, Zhou YB.

Bioorg Med Chem Lett. 2017 Dec 1;27(23):5154-5157. doi: 10.1016/j.bmcl.2017.10.059. Epub 2017 Oct 26.

PMID:
29100798
5.

Rational design of allosteric-inhibition sites in classical protein tyrosine phosphatases.

Chio CM, Yu X, Bishop AC.

Bioorg Med Chem. 2015 Jun 15;23(12):2828-38. doi: 10.1016/j.bmc.2015.03.027. Epub 2015 Mar 17.

6.

Calixarene-based phosphinic acids as inhibitors of protein tyrosine phosphatases.

Buldenko VM, Trush VV, Kobzar OL, Drapailo AB, Kalchenko VI, Vovk AI.

Bioorg Med Chem Lett. 2019 Mar 15;29(6):797-801. doi: 10.1016/j.bmcl.2019.01.026. Epub 2019 Jan 23.

PMID:
30704811
7.

Inhibition of SHP2 by new compounds induces differential effects on RAS/RAF/ERK and PI3K/AKT pathways in different cancer cell types.

Vazhappilly CG, Saleh E, Ramadan W, Menon V, Al-Azawi AM, Tarazi H, Abdu-Allah H, El-Shorbagi AN, El-Awady R.

Invest New Drugs. 2019 Apr;37(2):252-261. doi: 10.1007/s10637-018-0626-5. Epub 2018 Jun 27.

PMID:
29947013
8.

PTP1B suppresses prolactin activation of Stat5 in breast cancer cells.

Johnson KJ, Peck AR, Liu C, Tran TH, Utama FE, Sjolund AB, Schaber JD, Witkiewicz AK, Rui H.

Am J Pathol. 2010 Dec;177(6):2971-83. doi: 10.2353/ajpath.2010.090399. Epub 2010 Oct 15.

9.

Targeting a cryptic allosteric site for selective inhibition of the oncogenic protein tyrosine phosphatase Shp2.

Chio CM, Lim CS, Bishop AC.

Biochemistry. 2015 Jan 20;54(2):497-504. doi: 10.1021/bi5013595. Epub 2015 Jan 2.

10.

Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure.

Shen K, Keng YF, Wu L, Guo XL, Lawrence DS, Zhang ZY.

J Biol Chem. 2001 Dec 14;276(50):47311-9. Epub 2001 Oct 2.

11.

Discovery of a novel shp2 protein tyrosine phosphatase inhibitor.

Chen L, Sung SS, Yip ML, Lawrence HR, Ren Y, Guida WC, Sebti SM, Lawrence NJ, Wu J.

Mol Pharmacol. 2006 Aug;70(2):562-70. Epub 2006 May 22.

PMID:
16717135
12.

Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.

Grosskopf S, Eckert C, Arkona C, Radetzki S, Böhm K, Heinemann U, Wolber G, von Kries JP, Birchmeier W, Rademann J.

ChemMedChem. 2015 May;10(5):815-26. doi: 10.1002/cmdc.201500015. Epub 2015 Apr 15.

PMID:
25877780
13.

Fullerene derivatives as a new class of inhibitors of protein tyrosine phosphatases.

Kobzar OL, Trush VV, Tanchuk VY, Zhilenkov AV, Troshin PA, Vovk AI.

Bioorg Med Chem Lett. 2014 Jul 15;24(14):3175-9. doi: 10.1016/j.bmcl.2014.04.110. Epub 2014 May 5.

PMID:
24856066
14.

Synthesis and biological activity of a novel class of small molecular weight peptidomimetic competitive inhibitors of protein tyrosine phosphatase 1B.

Larsen SD, Barf T, Liljebris C, May PD, Ogg D, O'Sullivan TJ, Palazuk BJ, Schostarez HJ, Stevens FC, Bleasdale JE.

J Med Chem. 2002 Jan 31;45(3):598-622.

PMID:
11806712
15.

Docking Assisted Prediction and Biological Evaluation of Sideritis L. Components with PTP1b Inhibitory Action and Probable Anti-Diabetic Properties.

Eleftheriou P, Therianou E, Lazari D, Dirnali S, Micha A.

Curr Top Med Chem. 2019;19(5):383-392. doi: 10.2174/1568026619666190219104430.

PMID:
30806317
16.

Druggability analysis and classification of protein tyrosine phosphatase active sites.

Ghattas MA, Raslan N, Sadeq A, Al Sorkhy M, Atatreh N.

Drug Des Devel Ther. 2016 Sep 30;10:3197-3209. eCollection 2016.

17.

Phosphonate derivatives of tetraazamacrocycles as new inhibitors of protein tyrosine phosphatases.

Kobzar OL, Shevchuk MV, Lyashenko AN, Tanchuk VY, Romanenko VD, Kobelev SM, Averin AD, Beletskaya IP, Vovk AI, Kukhar VP.

Org Biomol Chem. 2015 Jul 21;13(27):7437-44. doi: 10.1039/c5ob00713e.

PMID:
26058329
18.

Docking analysis targeted to the whole enzyme: an application to the prediction of inhibition of PTP1B by thiomorpholine and thiazolyl derivatives.

Ganou CA, Eleftheriou PT, Theodosis-Nobelos P, Fesatidou M, Geronikaki AA, Lialiaris T, Rekka EA.

SAR QSAR Environ Res. 2018 Feb;29(2):133-149. doi: 10.1080/1062936X.2017.1414874.

PMID:
29347844
19.
20.

Comparative Analysis of Protein Tyrosine Phosphatases Regulating Microglial Activation.

Song GJ, Kim J, Kim JH, Song S, Park H, Zhang ZY, Suk K.

Exp Neurobiol. 2016 Oct;25(5):252-261. Epub 2016 Oct 20.

Supplemental Content

Support Center